HAS-BLED Bleeding Risk Score
Enter patient data to calculate the HAS-BLED score and estimate major bleeding risk during anticoagulation therapy.
Use the HAS-BLED Bleeding Risk Score
HAS-BLED Criteria
Check each criterion that applies to the patient. Hover the info icon for definitions.
Select criteria on the left and click Calculate Score.
HAS-BLED Score
Clinical Interpretation
Note: HAS-BLED is a risk-stratification aid, not a contraindication algorithm. Anticoagulation decisions must weigh stroke risk (CHA2DS2-VASc), bleeding risk, patient preference, and clinical context.
Active Risk Factors
Summary
The HAS-BLED score estimates the 1-year risk of major bleeding in patients with atrial fibrillation who are on anticoagulation therapy. Each letter of the acronym represents a modifiable or non-modifiable risk factor: Hypertension, Abnormal renal/liver function, Stroke history, Bleeding history/predisposition, Labile INR, Elderly (age over 65), and Drugs/alcohol use. A score of 3 or higher signals high bleeding risk and warrants closer monitoring rather than automatically stopping anticoagulation.
How it works
- Select whether each of the 7 HAS-BLED criteria applies to the patient.
- Each criterion present adds 1 point; abnormal renal AND liver function can each add 1 point (max 2 for that criterion).
- The total score ranges from 0 to 9.
- Scores of 0-1 indicate low risk, 2 indicates moderate risk, and 3 or above indicates high risk.
- High risk does not automatically mean anticoagulation should be stopped — it signals a need to correct reversible risk factors.
Use cases
- Assessing bleeding risk before starting anticoagulation in atrial fibrillation patients.
- Monitoring patients already on warfarin, dabigatran, rivaroxaban, or apixaban.
- Identifying modifiable bleeding risk factors to reduce a patient's score.
- Balancing stroke prevention (CHA2DS2-VASc) against bleeding risk.
- Clinical decision support in cardiology, internal medicine, and primary care.
- Patient education about their individual bleeding risk.